Enanta Pharmaceuticals INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Enanta Pharmaceuticals, Inc. announced the agenda for its Annual Meeting of Stockholders on March 11, 2026, including director elections and equity plan amendments.
NASDAQ
Enanta Pharmaceuticals, Inc. will hold its 2026 Annual Meeting to elect directors, approve a 1.6 million share increase for its equity incentive plan, and ratify executive compensation and auditor appointment.
NASDAQ
Enanta Pharmaceuticals announces its annual meeting of stockholders to be held on March 13, 2025, with key proposals including director elections, equity incentive plan amendment, executive compensation votes, and auditor ratification.
NASDAQ
Enanta Pharmaceuticals is asking stockholders to approve an amendment to its 2019 Equity Incentive Plan to increase the number of shares reserved for issuance by 800,000 at the virtual 2025 Annual Meeting on March 13, 2025.